JetBlue Airways Corporation vs Revvity Inc — how do they compare? JetBlue Airways Corporation trades at $3.84 (market cap $1.48B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 11.5× JetBlue Airways Corporation's market cap, and Revvity Inc pays a 0.18% dividend while JetBlue Airways Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and Revvity Inc for 12 Days on average.
| JBLU | RVTY | |
|---|---|---|
Market Cap | $1.48B | $16.98B |
Volume | 30,275,693 | 1,456,900 |
Sector | Industrials | Health |
52-Week High | $6.46 | $157.36 |
52-Week Low | $3.92 | $82.26 |
Typical Hold Time | 44 Days | 12 Days |
Enterprise Value | $8.84B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.92, down 1.26% with a bearish technical outlook. The airline faces fundamental challenges with negative net income margins (-9.32%) and declining revenue trends, though valuation metrics like P/S (0.15) appear attractive. Recent developments include route expansion to Colombia and new first-class seating, but the company continues to struggle with profitability amid high fuel costs and competitive pressures.
Investment outlook remains cautious with significant execution risks. While analyst consensus suggests moderate upside to the $5.89 price target, persistent losses and high debt levels (debt-to-asset ratio over 50%) create headwinds. The stock offers speculative value for investors betting on operational turnaround, but requires careful risk management given the challenging industry environment.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →